Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulised heparin for COVID-19 ARDS on helmet cPAP
2020-005863-29Phase 2Active
- Sponsor
- ASST Fatebenefratelli Sacco
- Start
- Aug 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing Nebulised unfractionated heparin with Placebo (2 arms). Primary endpoint: Days of cPAP use. Started Aug 2021; status: active.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-005863-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005863-29.